

# Paolo Ferrari

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6998193/paolo-ferrari-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

6,122  
citations

40  
h-index

73  
g-index

154  
ext. papers

7,816  
ext. citations

6.5  
avg, IF

5.51  
L-index

#	Paper	IF	Citations
148	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263328	3.7	2
147	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.. <i>Nature</i> , <b>2021</b> ,	50.4	204
146	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <b>2021</b> ,		16
145	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , <b>2021</b> , 184, 1171-1187.e20	56.2	331
144	Data and optimisation requirements for Kidney Exchange Programs. <i>Health Informatics Journal</i> , <b>2021</b> , 27, 14604582211009918	3	0
143	Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. <i>Science</i> , <b>2021</b> , 372, 1336-1341	33.3	33
142	A data-driven approach to identify risk profiles and protective drugs in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	18
141	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. <i>Lancet Regional Health - Europe, The</i> , <b>2021</b> , 1, 100013		29
140	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , <b>2021</b> , 373, 1109-1116	33.6	80
139	Crossing borders to facilitate live donor kidney transplantation: the Czech-Austrian kidney paired donation program - a retrospective study. <i>Transplant International</i> , <b>2020</b> , 33, 1199-1210	3	3
138	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , <b>2020</b> , 183, 1024-1042.e21	56.2	601
137	Pre- and postdonation kidney function in donors of a kidney paired donation with unique criteria for donor glomerular filtration rate - a longitudinal cohort analysis. <i>Transplant International</i> , <b>2019</b> , 32, 291-299	3	4
136	Early kidney allograft loss-Is there scope for improvement?. <i>Transplant International</i> , <b>2018</b> , 31, 864-866	3	
135	Challenges of kidney paired donation transplants involving multiple donor and recipient surgeons across Australia. <i>ANZ Journal of Surgery</i> , <b>2018</b> , 88, 167-171	1	7
134	Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. <i>Nephrology</i> , <b>2017</b> , 22, 114-117	2.2	14
133	Providing Better-Matched Donors for HLA Mismatched Compatible Pairs Through Kidney Paired Donation. <i>Transplantation</i> , <b>2017</b> , 101, 642-648	1.8	23
132	Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. <i>Nephrology</i> , <b>2017</b> , 22, 548-554	2.2	9

131	Diagnosing and preventing iron overload. <i>Hemodialysis International</i> , <b>2017</b> , 21 Suppl 1, S58-S67	1.7	14
130	Kidney Paired Donation and the "Valuable Consideration" Problem: The Experiences of Australia, Canada, and the United States. <i>Transplantation</i> , <b>2017</b> , 101, 1996-2002	1.8	2
129	Optimizing Outcomes in Pediatric Renal Transplantation Through the Australian Paired Kidney Exchange Program. <i>American Journal of Transplantation</i> , <b>2017</b> , 17, 534-541	8.7	22
128	Nurturing the benefits of pre-emptive kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 681-2	4.3	3
127	Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival. <i>Transplantation</i> , <b>2016</b> , 100, 1767-75	1.8	16
126	Outcomes of kidney paired donation transplants in relation to shipping and cold ischaemia time. <i>Transplant International</i> , <b>2016</b> , 29, 425-31	3	16
125	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. <i>Redox Report</i> , <b>2016</b> , 21, 14-23	5.9	5
124	Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2015</b> , 2, 33	2.3	4
123	A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 65, 49-57	7.4	21
122	Kidney paired donation: principles, protocols and programs. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 1276-85	4.3	76
121	Four years of experience with the Australian kidney paired donation programme. <i>Nephrology</i> , <b>2015</b> , 20, 124-31	2.2	24
120	Kidney paired donation: a plea for a Swiss National Programme. <i>Swiss Medical Weekly</i> , <b>2015</b> , 145, w14083.1	3.1	8
119	Comparison of computer tomographic volumetry versus nuclear split renal function to determine residual renal function after living kidney donation. <i>Acta Radiologica</i> , <b>2014</b> , 55, 753-60	2	28
118	Acute kidney injury due to decompression illness. <i>CKJ: Clinical Kidney Journal</i> , <b>2014</b> , 7, 380-2	4.5	3
117	Modeling the benefits and costs of integrating an acceptable HLA mismatch allocation model for highly sensitized patients. <i>Transplantation</i> , <b>2014</b> , 97, 769-74	1.8	14
116	Predictors of perioperative blood transfusions in patients with chronic kidney disease undergoing elective knee and hip arthroplasty. <i>Nephrology</i> , <b>2014</b> , 19, 404-9	2.2	24
115	Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. <i>Transplant Immunology</i> , <b>2013</b> , 29, 22-7	1.7	22
114	Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. <i>Transplant Immunology</i> , <b>2013</b> , 28, 148-53	1.7	44

113	Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. <i>Human Immunology</i> , <b>2013</b> , 74, 500-5	2.3	18
112	Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. <i>Nephrology</i> , <b>2013</b> , 18, 188-93	2.2	11
111	Response to Kute: Facilitators to national kidney paired donation program? <i>Transplant International</i> , <b>2013</b> , 26, e40-2	3	
110	ABO-incompatible matching significantly enhances transplant rates in kidney paired donation. <i>Transplantation</i> , <b>2013</b> , 96, 821-6	1.8	40
109	Travel-related disseminated <i>Penicillium marneffeii</i> infection in a renal transplant patient. <i>Transplant Infectious Disease</i> , <b>2012</b> , 14, 434-9	2.7	36
108	Comparison of time on the deceased donor kidney waitlist versus time on the kidney paired donation registry in the Australian program. <i>Transplant International</i> , <b>2012</b> , 25, 1026-31	3	16
107	High transplant rates of highly sensitized recipients with virtual crossmatching in kidney paired donation. <i>Transplantation</i> , <b>2012</b> , 94, 744-9	1.8	27
106	Assessment of reasons for not intensifying antihypertensive treatment in the Taiwanese population. <i>Journal of the Formosan Medical Association</i> , <b>2011</b> , 110, 768-74	3.2	
105	Diagnostic Investigations in Inherited Endocrine Disorders of Sodium Regulation <b>2011</b> , 210-234		2
104	Citrate anticoagulation using ACD solution A during long-term haemodialysis. <i>Nephrology</i> , <b>2011</b> , 16, 396-402	2.2	13
103	Virtual crossmatch approach to maximize matching in paired kidney donation. <i>American Journal of Transplantation</i> , <b>2011</b> , 11, 272-8	8.7	33
102	Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 702-8	4.3	45
101	Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 77-83	6.9	93
100	Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. <i>Nephrology</i> , <b>2010</b> , 15, 344-9	2.2	22
99	The role of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in human hypertension. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2010</b> , 1802, 1178-87	6.9	115
98	. <i>Clinical Therapeutics</i> , <b>2010</b> , 32, 397	3.5	1
97	Paired kidney donations to expand the living donor pool: the Western Australian experience. <i>Medical Journal of Australia</i> , <b>2009</b> , 190, 700-3	4	26
96	Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 1828-33	4.3	11

95	Licorice: a sweet alternative to prevent hyperkalemia in dialysis patients?. <i>Kidney International</i> , <b>2009</b> , 76, 811-2	9.9	10
94	The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 2926-30	4.3	20
93	Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. <i>Journal of Human Hypertension</i> , <b>2009</b> , 23, 151-9	2.6	40
92	Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. <i>Clinical Therapeutics</i> , <b>2009</b> , 31, 1652-63	3.5	35
91	Serum phosphate is an important determinant of corrected serum calcium in end-stage kidney disease. <i>Nephrology</i> , <b>2009</b> , 14, 383-8	2.2	21
90	Paired kidney donations to expand the living donor pool. <i>Journal of Nephrology</i> , <b>2009</b> , 22, 699-707	4.8	39
89	High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. <i>Nephrology</i> , <b>2008</b> , 13, 17-22	2.2	8
88	Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. <i>BMC Nephrology</i> , <b>2008</b> , 9, 8	2.7	12
87	Decline in native kidney function in liver transplant recipients is not associated with BK virus infection. <i>Liver Transplantation</i> , <b>2008</b> , 14, 1787-92	4.5	18
86	Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. <i>Nephrology</i> , <b>2007</b> , 12, 81-9	2.2	31
85	Venlafaxine to treat severe hypotension. <i>Nephrology</i> , <b>2007</b> , 12, 622	2.2	1
84	Hip pain in renal transplant recipients: symptomatic gluteus minimus and gluteus medius tendon abnormality as an alternative MRI diagnosis to avascular necrosis. <i>American Journal of Roentgenology</i> , <b>2007</b> , 188, 515-9	5.4	27
83	Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 1262-70	12.7	37
82	The challenge of renal cystic disease and its association with hypertension, age and abnormal potassium handling. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 1347-9	1.9	
81	Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 3176-84	12.7	80
80	A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity. <i>Journal of Molecular Endocrinology</i> , <b>2006</b> , 37, 71-80	4.5	12
79	Salt-sensitive blood pressure--an intermediate phenotype predisposing to diabetic nephropathy?. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 2113-9	4.3	9
78	Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 2414-9	4.3	54

77	Swiss Hypertension and Risk Factor Program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. <i>Blood Pressure</i> , <b>2005</b> , 14, 337-44	1.7	28
76	Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism. <i>Journal of Hypertension</i> , <b>2005</b> , 23, 460	1.9	
75	Apparent Addison's disease following ileostomy. <i>Nephrology</i> , <b>2005</b> , 10, 537-8	2.2	1
74	Comparison of continuous and intermittent renal replacement therapy for acute renal failure. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 1630-7	4.3	274
73	CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 1220-5	5.6	27
72	Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production. <i>Molecular and Cellular Endocrinology</i> , <b>2004</b> , 214, 167-74	4.4	11
71	Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. <i>Journal of Hypertension</i> , <b>2004</b> , 22, 377-81	1.9	76
70	Low prevalence of nonconservative mutations of serum and glucocorticoid-regulated kinase (SGK1) gene in hypertensive and renal patients. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 2499-504	4.3	13
69	Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. <i>Journal of Hypertension</i> , <b>2004</b> , 22, 1221-9	1.9	46
68	Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. <i>Nephrology Dialysis Transplantation</i> , <b>2003</b> , 18, 62-9	4.3	12
67	A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 2495-500	5.6	46
66	Forms of mineralocorticoid hypertension. <i>Vitamins and Hormones</i> , <b>2003</b> , 66, 113-56	2.5	12
65	The distinction between Liddle syndrome and apparent mineralocorticoid excess. <i>Pediatric Nephrology</i> , <b>2003</b> , 18, 607-8; author reply 609	3.2	2
64	Kidney transplantation in rats: an appraisal of surgical techniques and outcome. <i>Microsurgery</i> , <b>2003</b> , 23, 387-94	2.1	33
63	Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. <i>Kidney International</i> , <b>2003</b> , 63, 1564-73	9.9	106
62	Long-term calcineurin inhibition and magnesium balance after renal transplantation. <i>Transplant International</i> , <b>2003</b> , 16, 76-81	3	20
61	Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 17, 575-89	6.5	41
60	Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. <i>FASEB Journal</i> , <b>2003</b> , 17, 917-9	0.9	50

59	Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 2861-72	12.7	35
58	Genetics of the mineralocorticoid system in primary hypertension. <i>Current Hypertension Reports</i> , <b>2002</b> , 4, 18-24	4.7	20
57	Role of the alpha-adducin genotype on renal disease progression. <i>Kidney International</i> , <b>2002</b> , 61, 1270-5	9.9	29
56	Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. <i>Circulation</i> , <b>2002</b> , 105, e126; author reply e126	16.7	1
55	Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 2540-6	12.7	22
54	Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. <i>Journal of Hypertension</i> , <b>2002</b> , 20, 125-30	1.9	89
53	Salt-sensitivity of blood pressure and decreased 11beta-hydroxysteroid dehydrogenase type 2 activity after renal transplantation. <i>Transplantation</i> , <b>2002</b> , 74, 66-72	1.8	14
52	Recipient RAS gene variants and renal allograft function. <i>Transplantation</i> , <b>2002</b> , 73, 960-5	1.8	13
51	Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. <i>Transplantation</i> , <b>2002</b> , 74, 1147-52	1.8	55
50	Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 1105-13	6.2	16
49	Glycyrrhetic acid decreases plasma potassium concentrations in patients with anuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 191-196	12.7	32
48	Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. <i>Kidney International</i> , <b>2001</b> , 60, 46-54	9.9	86
47	Juvenile hypertension, the role of genetically altered steroid metabolism. <i>Hormone Research in Paediatrics</i> , <b>2001</b> , 55, 213-23	3.3	12
46	In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. <i>Hypertension</i> , <b>2001</b> , 38, 1330-6	8.5	116
45	A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 1247-52	5.6	39
44	Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. <i>American Journal of Medicine</i> , <b>2001</b> , 111, 692-8	2.4	210
43	A Mutation in the Cofactor-Binding Domain of 11β-Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 1247-1252	5.6	29
42	The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. <i>Journal of Hypertension</i> , <b>2000</b> , 18, 241-8	1.9	59

41	Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. <i>Kidney International</i> , <b>2000</b> , 58, 1413-9	9.9	20
40	Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. <i>Kidney International</i> , <b>2000</b> , 57, 1374-81	9.9	75
39	Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. <i>Annals of Hematology</i> , <b>2000</b> , 79, 523-6	3	103
38	Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 3745-9	5.6	122
37	Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus. <i>American Journal of Medicine</i> , <b>1999</b> , 106, 50-8	2.4	16
36	Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. <i>Transplant International</i> , <b>1999</b> , 12, 244-9	3	11
35	The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 4391-3	5.6	14
34	A genetic defect resulting in mild low-renin hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 10200-5	11.5	118
33	Endothelin-1 infusion inhibits plasma insulin responsiveness in normal men. <i>Journal of Hypertension</i> , <b>1998</b> , 16, 1279-84	1.9	18
32	A New Polymorphic Restriction Site in the Human 11β-Hydroxysteroid Dehydrogenase Type 2 Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 1814-1814	5.6	38
31	Oxoreductase and dehydrogenase activities of the human and rat 11beta-hydroxysteroid dehydrogenase type 2 enzyme. <i>Endocrinology</i> , <b>1997</b> , 138, 2948-52	4.8	45
30	Truncation of the N- and C-terminal regions of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. <i>Molecular and Cellular Endocrinology</i> , <b>1997</b> , 131, 173-82	4.4	23
29	The 11 beta-hydroxysteroid dehydrogenase type II enzyme: biochemical consequences of the congenital R337C mutation. <i>Steroids</i> , <b>1996</b> , 61, 197-200	2.8	23
28	Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. <i>Molecular and Cellular Endocrinology</i> , <b>1996</b> , 119, 21-4	4.4	49
27	Rat 11 beta-hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the placenta and is modulated by adrenal steroids in the kidney. <i>Molecular and Cellular Endocrinology</i> , <b>1996</b> , 120, 67-75	4.4	41
26	Reduced plasma cyclic GMP but normal renal responses to atrial natriuretic factor in pre-hypertension. <i>Blood Pressure</i> , <b>1996</b> , 5, 16-26	1.7	9
25	Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. <i>Lancet, The</i> , <b>1993</b> , 341, 327-31	4.0	100
24	Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. <i>European Journal of Clinical Pharmacology</i> , <b>1993</b> , 44, 457-62	2.8	29



23	Serum Lipoproteins During Treatment with Antihypertensive Drugs. <i>Journal of Cardiovascular Pharmacology</i> , <b>1993</b> , 22, 98-105	3.1	30
22	Enhanced blood pressure response to mineralocorticoid stimulation in normotensive members of hypertensive families. <i>Blood Pressure</i> , <b>1992</b> , 1, 86-91	1.7	5
21	Left ventricular structure and determinants in normotensive offspring of essential hypertensive parents. <i>Journal of Hypertension</i> , <b>1992</b> , 10, 1257-64	1.9	9
20	Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients. <i>Drugs</i> , <b>1992</b> , 44 Suppl 1, 74-84	12.1	4
19	Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. <i>European Journal of Clinical Pharmacology</i> , <b>1992</b> , 42, 275-80	2.8	25
18	Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. <i>Kidney International</i> , <b>1992</b> , 41, 369-74	9.9	77
17	Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects. <i>Journal of Cardiovascular Pharmacology</i> , <b>1991</b> , 18, 106-10	3.1	9
16	Atrial natriuretic factor after cardiac surgery with cardiopulmonary bypass in children. <i>Critical Care Medicine</i> , <b>1991</b> , 19, 1497-502	1.4	6
15	Abnormalities of insulin and lipid metabolism in Milan hypertensive rats. <i>American Journal of Hypertension</i> , <b>1991</b> , 4, 773-5	2.3	43
14	Antihypertensive agents, serum lipoproteins and glucose metabolism. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 26B-35B	3	56
13	Reproducibility of insulin sensitivity measured by the minimal model method. <i>Diabetologia</i> , <b>1991</b> , 34, 527-30	10.3	61
12	Unaltered insulin sensitivity during calcium channel blockade with amlodipine. <i>European Journal of Clinical Pharmacology</i> , <b>1991</b> , 41, 109-13	2.8	16
11	Central role of sodium in hypertension in diabetic subjects. <i>Diabetes Care</i> , <b>1991</b> , 14, 220-32	14.6	92
10	Antihypertensive therapy with Ca <sup>2+</sup> antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. <i>Diabetes Care</i> , <b>1991</b> , 14, 911-4	14.6	32
9	Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. <i>American Journal of Medicine</i> , <b>1991</b> , 91, 589-96	2.4	185
8	Insulin, insulin sensitivity and hypertension. <i>Journal of Hypertension</i> , <b>1990</b> , 8, 491-500	1.9	129
7	Dysregulation of atrial natriuretic factor in hypertension-prone man. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1990</b> , 71, 944-51	5.6	40
6	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> ,	50.4	44

5	Oxoreductase and Dehydrogenase Activities of the Human and Rat 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Enzyme	17
4	Defective neutralizing antibody response to SARS-CoV-2 in vaccinated dialysis patients	2
3	A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery	13
2	ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies	3
1	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages	5